Here we present Translocatome, the first dedicated database of human translocating proteins (URL: http://translocatome.linkgroup.hu). The core of the Translocatome database is the manually curated data set of 213 human translocating proteins listing the source of their experimental validation, several details of their translocation mechanism, their local compartmentalized interactome, as well as their involvement in signalling pathways and disease development. In addition, using the well-established and widely used gradient boosting machine learning tool, XGBoost, Translocatome provides translocation probability values for 13,066 human proteins identifying 1133 and 3268 highand low-confidence translocating proteins, respectively. The database has user-friendly search options with a UniProt autocomplete quick search and advanced search for proteins filtered by their localization, UniProt identifiers, translocation likelihood or data complexity. Download options of search results, manually curated and predicted translocating protein sets are available on its website. The update of the database is helped by its manual curation framework and connection to the previously published ComPPI compartmentalized protein-protein interaction database. As shown by the application examples of merlin (NF2) and tumor protein 63 (TP63) Translocatome allows a better comprehension of protein translocation as a systems biology phenomenon and can be used as a discovery-tool in the protein translocation field.
INTRODUCTION
Subcellular localization of proteins is essential in spatial and temporal organisation of biological processes such as signalling pathways enabling their separation into organelles (1) . Translocating proteins play a key role in the reconfiguration of cellular functions after environmental changes, as well as in embryonic or disease development. Different subcellular organelles have well characterized interactomes (2, 3) . With the advance of imaging techniques subcellular dynamics became a rapidly expanding research area (4, 5) . Restoring or affecting the cellular localization of disease-related proteins emerges as an efficient therapeutic method (6, 7) .
Protein translocation is a process which refers to the alteration of a given protein's subcellular localization. However, this phenomenon has no unified definition, and the word "translocation" may also refer to gene translocation or RNA translocation at the ribosome. In this work we define protein translocation as a systems biology phenomenon, which refers to the regulated movement of a protein of a given post-translational state between subcellular compartments. Translocation changes the interaction partners and leads to altered function(s) of translocating proteins. There are certain processes (such as co-translational, post-translational delivery-type, cell division-induced, downregulation-or passive diffusion-related phenomena; for their detailed description see Supplementary Texts S1 and S2) that may change the localization of a protein, but to increase the focus and clarity of our database we did not consider them as translocation.
There are widely used protein databases that contain information on protein translocation, e.g. the MoonProt (8) or UniProt (9) databases. However, these databases are not dedicated collections of translocating proteins. Here we present Translocatome, which is a manually curated database of 213 human translocating proteins with extensive information on their translocation. Moreover, Translocatome contains 13 066 human proteins with predicted likelihood of translocation. With the help of the well-established and widely used gradient boosting machine learning tool, XGBoost (10) (11) (12) we predicted 1133 high-confidence translocating proteins. In addition, Translocatome contains 3268 and 8665 low-confidence and non-translocating proteins, respectively. To train the XGBoost algorithm, we also created a manually curated set of 139 non-translocating proteins as part of the database.
Translocatome is a novel, dedicated database of human translocating proteins including their interaction partners in the different subcellular localizations. This database contributes to a better understanding of protein translocation as a systems biology phenomenon and facilitates further discoveries of translocating proteins. As translocating proteins are already targeted pharmaceutically (6, 7) new findings in this field may also lead to better therapeutic options.
DESCRIPTION OF THE DATABASE

Overview of Translocatome
Translocatome is the first database that collects manually curated human translocating proteins including their interacting partners in the localizations involved, translocation mechanism (including protein structure details if available), type of experimental evidence, affected signalling pathway(s) and pathological properties. The core of the Translocatome database is the 213 manually curated human translocating proteins (http://translocatome.linkgroup.hu/coredata) which were all collected based on related publications containing experimental evidence. Altogether Translocatome contains 13 066 human proteins, which were selected from the compartmentalized protein-protein interaction database (3; ComPPI http://comppi.linkgroup.hu, downloaded on 20/07/2018) using the inclusion criterion that every protein needed to have at least one experimentally validated subcellular localization. By the application of the well-established gradient boosting machine learning tool, XGBoost (10-12) we predicted 1133 high-confidence translocating proteins. All the 13 066 human proteins were characterized by their translocation likelihood named as Translocation Evidence Score (TES) calculated by the XGBoost machine learning algorithm ( Figure 1 ). Various search and download options make it possible for users to process these data according to their goals.
Database content
The core data of Translocatome is the extensively curated set of 213 human translocating proteins (see Core Data at the website: http://translocatome.linkgroup.hu/coredata). With the manual curation process involving the judgement of 3 independent experts we aimed to collect detailed and experimentally validated information about every entry extracted from peer reviewed publications (for the details of the manual curation process see Supplementary Text S3, Supplementary Table S1 and Supplementary Figure S1 ). For each of the 213 manually curated translocating proteins we collected the available subset of the following data: a.) name set, gene name and UniProt (9) accession number and link, b.) PubMed ID(s) and link(s) to peer-reviewed article(s) describing the experimental evidence of translocation, c.) initial and target localizations of the translocating protein, d.) interacting partners and biological functions (both in the initial and target compartments), e.) translocation mechanism, f.) the used detection method, g.) protein structural information on translocation mechanism, h.) disease group, exact disease involved and pathological role, i.) signalling pathways affected.
We used the UniProt naming convention (9) for protein identification, Gene Ontology terms (13, 14) for localization/biological process identification and the KEGG naming convention (15) for the standardization of signalling pathways. Following the logic of our previously published compartmentalized protein-protein interaction database (ComPPI, 3) every protein was annotated with one of six major cellular localizations (cytoplasm, extracellular space, mitochondria, nucleus, membrane or secretory-pathway). If there was more precise localization information available it was included as a minor localization. All 213 manually curated translocating proteins are characterized by a Data Complexity Score (DCS) as described later in detail, which makes it easier to assess the amount of information associated with each protein. 53 of the manually curated proteins showed translocation exclusively under pathological conditions (such as cancer). Therefore, we used the remaining 160 physiologically translocating proteins as a positive training set ( Supplementary Table   S2 ) for the widely used XGBoost machine learning algorithm (10) (11) (12) .
We also collected a manually curated negative dataset of 139 human non-translocating proteins, each one classified as a protein a.) with experimentally proved diffuse, multi-compartmental distribution, b.) with exclusive single-compartment localization, c.) docked to DNA/RNA, d.) embedded in membranes or e.) attached to the cytoskeleton (for additional details see Supplementary Text S4).
These 139 proteins were used as a negative training set ( Supplementary Table S3 ) for the application of the XGBoost machine learning algorithm (10) (11) (12) . For a detailed description of our database structure see Figures 1A and 1B.
Altogether Translocatome contains 13 066 human proteins having at least one experimentally validated localization as described in our in house developed compartmentalized protein-protein interaction database (ComPPI, 3). From the ComPPI database we also imported the interactome of these human proteins having 151 889 interactions. The translocation likelihood of all the 13 066 proteins is characterized by a Translocation Evidence Score (TES) as described later in detail. The translocation likelihood was calculated by the XGBoost machine learning algorithm (10) (11) (12) as detailed in the next Section.
The XGBoost machine learning algorithm-based prediction of translocating proteins
The machine learning procedure followed the general methodology of supervised machine learning workflow: data collection, feature extraction, feature selection, classification, training, testing and interpretation. For each step we applied an existing, well-characterized approach. Data collection and feature extraction were based on established procedures as described below. For all additional steps we applied the well-established, widely used gradient boosting-type (10) machine learning tool, XGBoost (11) . XGBoost was successfully applied in hundreds of recent studies to predict e.g. hostpathogen protein-protein interactions (16) , microRNA disease association (17) and DNA methylation (18) . Several studies including our own previous paper showed that XGBoost gives the best performance if compared with a number of known machine learning methods (see e.g. Refs. 12, 16 and 18).
To train the XGBoost method first we annotated each of the 13 066 proteins of the Translocatome database with their relevant Gene Ontology (GO, 13,14) cellular component, biological process and molecular function terms also including their ancestors. This resulted in 21 020 annotated GO terms total (all details of the methodology are available here: https://github.com/kerepesi/translocatome_ml).
The process was based on our previous work (12) , for its details please see Supplementary Text S5.
Next, each of the 13 066 proteins were annotated with their degree and bridgeness in the compartmentalized protein-protein interaction database (ComPPI, 3) derived human interactome containing 151 889 interactions. Degree (the number of human interactome neighbours) was included, since the 213 manually curated translocating proteins showed a significantly higher degree than that of the 139 manually curated non-translocating proteins or the average (Supplementary Figure S2 ). This is not surprising since translocating proteins often have a central role in regulation behaving as interactome hubs. Similarly, translocating proteins often connect interactome modules (large protein mega-complexes), thus act as bridges. Indeed, the 213 manually curated translocating proteins had significantly higher bridgeness values than that of the 139 manually curated non-translocating proteins or the average (Supplementary Figure S2 ). Degree and bridgeness values were calculated using the CytoScape network analyser program (19) and its ModuLand plug-in (20) , respectively. GO terms, degree and bridgeness formed the feature sets selected by the XGBoost machine learning method.
Since the human interactome (3) we used for the calculation of degree and bridgeness did not contain interactions observed in pathological conditions, we excluded those 53 of the manually curated proteins from the positive training set of the XGBoost algorithm, which showed translocation exclusively under pathological conditions (such as cancer). The remaining 160 manually curated proteins were used as the positive training set ( Supplementary Table S2 ).
Following the methodology of several XGBoost studies (11, (16) (17) (18) including our previously published work (12) we evaluated the XGBoost-selected feature sets by 5-fold cross-validation, and we evaluated their predictive power by the area under the curve of the receiver operating characteristic curve (ROC AUC or shortly AUC, 21). 5-fold cross-validation is a widely used method where the training data is split into five random parts and four parts are used to train the XGBoost machine learning tool and the prediction of the fifth part is evaluated. For every feature set, we repeated this process 100 times. We selected those GO features which had a feature important value (produced by the XGBoost program) greater than 0.02. With this generally applied XGBoost procedure we reached an average AUC of 0.916 (±0.0046 standard deviation) with only 15 GO features left from the initial 21 020 (see Table 1 ). We continued feature selection by adding the two interactome-derived features degree and bridgeness using the giant component of the ComPPIderived human protein-protein interaction network (1) . In these calculations the giant component of the interactome was used which did not contain 9 proteins of the total. The inclusion of the two network-related features produced an average AUC of 0.9207 (±0.0056 standard deviation), showing a further increase from the average AUC of 0.916 and implying a high performance. We show the ROC curves of 100 five-fold cross-validation runs of the final feature set on Figure 1C having a minimal, average and maximal AUC of 0.9047, 0.9207 and 0.9333, respectively. As shown on Supplementary Figure S3 both precision-recall and Matthews correlation coefficient curves also showed a high performance of the learning process. For more details of the generally applied machine learning procedure see Supplementary Text S6. All data of the procedure are available at https://github.com/kerepesi/translocatome_ml along with codes to reproduce the results.
The feature set of the XGBoost model with the best AUC value is shown on Table 1 . Features with positive importance values increase the probability of translocation. These are Gene Ontology features from each main GO category (cellular components, biological processes and molecular functions), which are often associated with protein translocation as described in Table 1 in detail. If a feature has a negative importance value, then it decreases the probability of translocation. Two categories of low degree and low bridgeness values each, as well as 6 GO-terms negatively associated with protein translocation are listed among these negative features. Using the feature set shown on Table 1 we calculated the Translocation Evidence Score characterizing the translocation probability of each of the 13 066 proteins in the Translocatome database as described in the next section.
Data Complexity and Translocation Evidence Scores
Data Complexity Score. To provide an easy assessment of the information available of a manually curated protein we developed the Data Complexity Score (DCS). DCS varies between 0 and 1, having increasing values if the protein has more curated data. The score is calculated and normalized after weighting all the available data, where those related to translocation have a higher weight (please find the detailed calculation process in Supplementary Text S7). Therefore, DCS is not only shows the quantity but also the relevance of the available data. In addition DCS indicates which entries may require further curation.
Translocation Evidence Score. The XGBoost machine learning method gave every protein of the Translocatome database a Translocation Evidence Score (TES) that is proportional with the translocation probability of the given protein. For each protein we computed TES using Equation 1
(1), where w i is the importance value of the i th feature of the model (see i th row of Table 1 ). The importance value was calculated as described in the legend of Table 1 . x = 1 , if the given feature is true for that protein and x = 0, if it is false (n is the number of features of the model; here n=19). TES values were rescaled to the interval [0,1] by min-max normalization using Equation 2
.
(2),
The larger the TES value, the greater the probability of translocation. As a numerical example, suppose that "protein A" has 20 neighbours (degree) in the human interactome and its UniProt record contains only two GO terms, "animal organ morphogenesis'', and "cytoplasm''. Then the predicted translocation evidence score of "protein A" is -0.497 + 2.675 + 1.353 = 3.531. The value is then normalized using Equation 2. For each of the 13 066 proteins, the respective TES scores can be found both in the search results and in the downloadable datasets.
The Translocation Evidence Score gave the possibility to define a cut-off value, below which proteins were considered as non-translocating. To define this cut-off value, we used the widely used measure of a test's accuracy, the F1 score (also called as F-measure, 22) that measures the performance of a binary classification being a harmonic average of precision and recall (also called as sensitivity). Supplementary Figure S4 shows recall, fallout, precision and the F1 score at different threshold values and illustrates the distribution of the TES values. The F1 score reached its maximum at the threshold of -0.02958, which gives a straightforward cut-off value for translocation probability.
Thus proteins having lower TES values than 0.4487 were considered as non-translocating (for more details see Supplementary Texts S6 and S8). In order to give an assessment of potential false positive predictions we also defined a higher TES cut-off value separating low-and high-confidence translocating proteins. We set this value as 0.6167, since above this threshold there were not any negative set proteins. We assume that the probability of false positive predictions is low above this threshold value. Low-confidence translocating proteins, which have a translocation evidence score (TES) between the two threshold values are presumably translocating but they need further validation.
The two Translocation Evidence Score cut-off values separated our original 13 066 human proteins to 3 classes: a.) 1133 high-confidence translocating proteins having a TES value higher than 0.6167; b.) 3268 low-confidence translocating proteins having a TES value between 0.6167 and 0.4487, as well as c.) the residual 8665 proteins having a TES value lower than 0.4487, which were considered as non-translocating ( Figure 1B) .
Search, download options and output
As part of the user-friendly interface, various search functions were developed. We provide an easy to 
Application examples
The Translocatome database is the only dedicated collection of human translocating proteins. With its Translocation Evidence Score (TES) for 13 066 proteins it helps the identification and experimental validation of novel translocating proteins. To demonstrate the prediction efficiency of Translocatome we assessed the first 40 proteins with the highest TES values. Table 2 . shows the list of the best performing 25 proteins. They fall into 4 categories: A.) were already included in the manually curated 213 translocating protein set (12 proteins: PTEN, PTK2, FOXO3, GMNN, ATF2, MAPK1, GLI3, HRAS, AR, SMAD3, SMAD2 and HSP90AB1); B.) were previously shown to be translocating proteins but have not appeared in our Core Data of 213 proteins collected from keyword-based searches (11 proteins: NF2, TULP3, SNCA, FGFR2, MTOR, GSK3B, EIF6, HDAC1, CARM1, CUL1 and RARB;
see Supplementary Table S4 ); C.) have not been described as translocating proteins yet, but from the The best hit of the XGBoost algorithm, the PTEN protein is a part of the manually curated 213 translocating proteins. As its second best hit, the XGBoost algorithm correctly predicted NF2 (Merlin) as a translocating protein, since NF2 in its dephosphorylated form indeed translocates to the nucleus (23) . NF2 is a hub having 48 neighbours and was characterized by 6 out of the 15 Gene Ontology terms that were important according to the best XGBoost model predicting translocation.
Out of the 25 proteins listed on Table 2 , the p63 protein (tumor protein 63, TP63) is the only protein, which falls into the category C.) containing "proteins having implications in the literature that they are translocating". p63 is not tagged as translocating in available databases (8, 9) . p63 is a protein that is physiologically found in the nucleus of human cells (Figure 2) . It acts as a transcription factor either activating or repressing specific DNA sequences (24) and it is an essential factor during embryogenesis (25) . Besides these conventional functions it is also known that p63 appears in the cytoplasm of adenocarcinoma or prostate carcinoma cells. Moreover, the cytoplasmic localization of p63 results in the increased malignancy of these tumours (26, 27) . This disease-altered localization of p63 is in compliance with our definition for a translocating protein. Thus, the XGBoost machine learning algorithm correctly predicted the translocation of p63. As p63 is associated with poor survival of cancer patients (26, 27) its targeting may serve as a therapeutic option.
With the above examples we demonstrated that the XGBoost machine learning algorithm (10) (11) (12) is able to classify previously known proteins effectively and may also predict new translocations correctly. Out of the 25 best hits shown on Table 2 the PRKRA protein (Interferon-inducible doublestranded RNA-dependent protein kinase activator A) is the only one, which appears to be a completely new translocating protein candidate. It will be an interesting question of further experimental studies, whether this protein is indeed translocating or shuttling between the cytosol and the nucleus as predicted by the rather equal number of its protein interactions (3) in these two compartments.
Comparison with similar tools
The existing MoonProt (8) and UniProt (9) Translocatome is available at http://translocatome.linkgroup.hu. Translocatome is a communityannotation resource, which is helped by its manual curation framework (MCF). MCF allows the users to build in their own experimentally verified translocating proteins. Translocatome will be updated and upgraded annually for minimum 5 years. The Translocatome database is connected to our previously developed, compartmentalized protein-protein interaction database (ComPPI, 3). Thus the improvement of the subcellular localization and interactome data can be easily translated to regular updates of the Translocatome database giving improved protein translocation likelihood values.
We plan to resolve current Translocatome limitations, such as extending the database to other species than humans. Future plans include the extension of positive and negative datasets and localization-based network visualization. Translocating RNAs play a key role in subcellular regulation as well, but their role is even more complex and mysterious. We plan to extend our database and add translocating RNAs, to fill out this gap. The improvement of the data not only means, that
Translocatome will have more proteins or more detailed information. In this process the whole database will be updated meaning that the XGBoost machine learning will reappraise the data and provide more even accurate predictions based on the updated data.
In conclusion, the Translocatome database introduced here provides the first dedicated collection of 213 translocating human proteins including their interaction partners in the different subcellular localizations. Importantly, Translocatome gives a Translocation Evidence Score to more than 13 thousand human proteins allowing the assessment of their translocation probability. All these features are accessible in a user-friendly manner. The Translocatome database allows a better comprehension of protein translocation as a systems biology phenomenon, and can be used as a discovery-tool of the field. Since translocating proteins become more and more important therapeutic targets (6, 7) Translocatome may contribute to the development of better future therapeutic options.
AVAILABILITY
The Translocatome database of human translocating proteins can be accessed freely at http://translocatome.linkgroup.hu.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online. (13, 14) , as listed in the first column. XGBoost assigns each feature with an importance score (as shown in the third column) which was calculated as the leaf-scores of the one-depth trees of the best XGBoost model. In the fourth column there is a short (and most of the time, very partial) explanation to explain why these features may become selected by the XGBoost machine learning process as best predictors of protein translocation including some key references supporting the explanations. and Translocation Evidence Score (TES) as defined in the main text. The higher the TES score the higher the probability of translocation. Proteins fall into four categories as shown in the fifth column. A.)
The protein was included in the manually curated 213 translocating protein set. B.) The protein did not appear in our keyword-based searches but was previously shown to be a translocating protein. C.)
The protein has not been described as a translocating protein yet, but from the literature we can conclude that its translocation is probable (p63 protein, for more information, see Figure 2 ). D.) There is no information in the literature about the translocation of this protein (PRKRA). Categories C and D are good candidates for further evaluation. Short summary gives a brief description of the translocation mechanism of each protein having a representative publication cited in categories B and C (for references describing the translocation of proteins in category A see the Translocatome database entry of the respective protein).
